# A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

> **NCT00857571** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 150 mg Suspension
- **DRUG:** 30 mg Suspension
- **DRUG:** 400 mg Suspension
- **DRUG:** 5 mg Suspension
- **DRUG:** 750 mg Suspension
- **DRUG:** 150 mg Tablet
- **DRUG:** 30 mg Tablet
- **DRUG:** 400 mg Tablet
- **DRUG:** 5 mg Tablet
- **DRUG:** 750 mg Tablet

## Key facts

- **NCT ID:** NCT00857571
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00857571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00857571, "A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00857571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*